Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Intra-Cellular Therapies, Inc.
  6. News
  7. Summary
    ITCI   US46116X1019

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
46.99 USD   -1.59%
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform Rating
MT
01/09Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
01/09Transcript : Intra-Cellular Therapies, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 11:15 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Intra-Cellular Therapies, Inc., Q1 2022 Earnings Call, May 10, 2022

05/10/2022 | 08:30am EST
share with twitter
share with LinkedIn
share with facebook
Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies first quarter earnings call. [Operator Instructions] As a reminder, today's conference call is being recorded. I'd now...


© S&P Capital IQ 2022
All news about INTRA-CELLULAR THERAPIES, INC.
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform..
MT
01/09Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
01/09Transcript : Intra-Cellular Therapies, Inc. Presents at 41st Annual J.P. Morg..
CI
01/03Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conferenc..
AQ
2022Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2022Insider Sell: Intra-Cellular Therapies
MT
2022Insider Sell: Intra-Cellular Therapies
MT
2022Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations a..
AQ
2022Insider Sell: Intra-Cellular Therapies
MT
2022Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
AQ
More news
Analyst Recommendations on INTRA-CELLULAR THERAPIES, INC.
More recommendations
Financials (USD)
Sales 2022 249 M - -
Net income 2022 -270 M - -
Net cash 2022 272 M - -
P/E ratio 2022 -16,4x
Yield 2022 -
Capitalization 4 450 M 4 450 M -
EV / Sales 2022 16,8x
EV / Sales 2023 9,54x
Nbr of Employees 512
Free-Float 97,4%
Chart INTRA-CELLULAR THERAPIES, INC.
Duration : Period :
Intra-Cellular Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTRA-CELLULAR THERAPIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 46,99 $
Average target price 69,62 $
Spread / Average Target 48,1%
EPS Revisions
Managers and Directors
Sharon Mates Chairman, President & Chief Executive Officer
Lawrence J. Hineline Chief Financial Officer, Treasurer & SVP-Finance
Robert E. Davis Chief Scientific Officer & Senior Vice President
Suresh Durgam Chief Medical Officer & Senior Vice President
Karen Patruno Sheehy Chief Compliance Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
INTRA-CELLULAR THERAPIES, INC.-9.77%4 522
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
WUXI APPTEC CO., LTD.18.94%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008